Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR)

被引：15
|
作者：
Lee, J.
Hirsh, V.
Park, K.
Qin, S.
Blajman, C. R.
Perng, R.
Emerson, L.
Langmuir, P. B.
Manegold, C.
机构：
[1] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[2] McGill Univ Hlth Ctr, Montreal, PQ, Canada
[3] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[4] 81 Hosp Chinese Peoples Liberat Army, Nanjing, Jiangsu, Peoples R China
[5] Isis Ctr Especializado, Rosario, Santa Fe, Argentina
[6] Vet Gen Hosp, Taipei, Taiwan
[7] AstraZeneca, Loughborough, Leics, England
[8] AstraZeneca, Wilmington, DE USA
[9] Univ Med Ctr, Mannheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7525
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
    Lee, S.
    Rudd, R. M.
    Woll, P. J.
    Ottensmeier, C. H.
    James, L. E.
    Gower, N. H.
    Spiro, S. G.
    Jitlal, M.
    Hackshaw, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Randomized, double-blind, placebo-controlled, phase III multicentre study of paclitaxel plus carboplatin (TC) versus TC plus endostar in patients with advanced non-small cell lung cancer (NSCLC)
    Han Baohui
    Xiu Qingyu
    Wang Huiming
    Luo Yi
    Bai Chunxue
    Guo Shuliang
    Liu Wenchao
    Zhuang Zhixiang
    Zhang Yang
    Zhou Jianying
    Jing Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S354
  • [33] A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
    Zhao, Hongyun
    Zhang, Zhonghan
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Yang, Yunpeng
    Zhang, Yang
    Huang, Yan
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, Baohui
    Li, Kai
    Zhao, Yizhuo
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    He, Jianxing
    Shi, Yuankai
    Cheng, Yin
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Zhou, Jianying
    Chen, Yinlan
    Wang, Donglin
    Zhou, Xin
    Yu, Yan
    Chen, Liming
    Liu, Anwen
    Huang, Jianjin
    Huang, Cheng
    Cao, Bangwei
    Chen, Jun
    Ma, Rui
    Yu, Zhuang
    Ding, Cuimin
    Wang, Hongbing
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S886 - S887
  • [35] Vandetanib plus pernetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL)
    de Boer, Richard H.
    Arrieta, Oscar
    Gottfried, Maya
    Blackhall, Fiona H.
    Raats, Johann
    Yang, Chih-Hsin
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S356 - S357
  • [36] RESOURCE UTILIZATION BY HISTOLOGY FOR PEMETREXED AS MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND PHASE III TRIAL
    Zielinski, C.
    Feng, J.
    Gangadharan, V.
    Zhang, Y.
    Metzner, D.
    Hongming, P.
    Liepa, A. M.
    Peterson, P.
    Orlando, M.
    Oramas, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 97 - 98
  • [37] CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
    Garon, Edward B.
    Ardizzoni, Andrea
    Barlesi, Fabrice
    Cho, Byoung Chul
    De Marchi, Pedro
    Goto, Yasushi
    Kowalski, Dariusz M.
    Lu, Shun
    Paz-Ares, Luis G.
    Spigel, David R.
    Spira, Alexander, I
    Thomas, Michael
    Leung, Mimi
    Baum, Jason
    Zhu, Zewen
    Oliveira Portella, Maria do Socorro
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [39] Disease control with a second epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) after failure of a first TKI in Asian patients with non-small cell lung cancer (NSCLC)
    Wong, A.
    Lim, S. W.
    Chin, T. M.
    Soong, R.
    Soo, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] The predictive value of serum tumour markers in Tyrosine Kinase Inhibitor (TKI) treatment for advanced non-small cell lung cancer (NSCLC)
    Pearmain, L.
    Crawford, S. M.
    LUNG CANCER, 2011, 71 : S5 - S5
12345